» Articles » PMID: 31483167

Examining the Relationship Between Pre- and Postprandial Glucose Levels and Insulin Bolus Timing Using Bluetooth-Enabled Insulin Pen Cap Technology and Continuous Glucose Monitoring

Overview
Date 2019 Sep 5
PMID 31483167
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Timing of insulin administration in persons using multiple daily injections (MDI) is self-reported. New technology enabling tracking and logging of insulin doses, combined with continuous glucose monitoring (CGM), may provide insight into the relationship between insulin administration and glucose levels. We performed a prospective observational study using Bluetooth-enabled pen caps, along with CGM, in participants with type 1 diabetes (T1D) on MDI to objectively assess the relationship between the timing of insulin administration and its impact on pre- and postprandial glucose levels for a 2-week period. We evaluated 50 participants (age 40.3 ± 19 years; A1c 8.2% ± 1.5%, duration of T1D 20 ± 15 years). Thirty-seven percent of total boluses resulted in persistent hyperglycemia (glucose >180 mg/dL 3 h postprandially), while 10% resulted in clinically significant hypoglycemia (glucose <55 mg/dL 3 h postprandially) on CGM. Preprandial glucose levels at the time of the bolus did not correlate with postprandial glucose levels. Late boluses, defined as a rise in glucose of ≥50 mg/dL before a bolus, were seen two times/patient/week. Missed boluses, defined as a rise in glucose of ≥50 mg/dL without a bolus within 2 h, occurred 17 times/patient/week. Late and missed boluses were associated with worse glycemic control (A1c;  = 0.1,  = 0.02;  = 0.1,  = 0.02). The use of Bluetooth-enabled pen caps, with CGM, in persons with T1D on MDI can illustrate the relationship between insulin bolus timing and postprandial glucose. These data may help clinicians and patients understand the impact of timing of insulin doses on glucose levels and glycemic control.

Citing Articles

First validity testing of GluciQuizz, a French self-questionnaire evaluating carb-counting for patients with type 1 diabetes.

Tatulashvili S, Dreves B, Cosson E, Meyer L, Morello R, Joubert M PLoS One. 2025; 20(2):e0318746.

PMID: 39999057 PMC: 11856297. DOI: 10.1371/journal.pone.0318746.


Impact of Missed and Late Meal Boluses on Glycemic Outcomes in Automated Insulin Delivery-Treated Children and Adolescents with Type 1 Diabetes: A Two-Center, Population-Based Cohort Study.

Laugesen C, Ritschel T, Ranjan A, Hsu L, Jorgensen J, Svensson J Diabetes Technol Ther. 2024; 26(12):897-907.

PMID: 38805311 PMC: 11693967. DOI: 10.1089/dia.2024.0022.


Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting.

Danne T, Joubert M, Hartvig N, Kaas A, Knudsen N, Mader J Diabetes Care. 2024; 47(6):995-1003.

PMID: 38569055 PMC: 11116913. DOI: 10.2337/dc23-2176.


Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen.

MacLeod J, Im G, Smith M, Vigersky R Diabetes Technol Ther. 2023; 26(1):33-39.

PMID: 37855818 PMC: 10794824. DOI: 10.1089/dia.2023.0365.


Connected Insulin Pens and Caps: An Expert's Recommendation from the Area of Diabetes of the Spanish Endocrinology and Nutrition Society (SEEN).

Tejera-Perez C, Chico A, Azriel-Mira S, Lardies-Sanchez B, Gomez-Peralta F Diabetes Ther. 2023; 14(7):1077-1091.

PMID: 37188930 PMC: 10241765. DOI: 10.1007/s13300-023-01417-1.